Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Matt Breese

Manager, Marketing at MMIT
Find me on:

Recent Posts

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2018)

Posted by Matt Breese on Oct 19, 2018

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty

MMIT Reality Check on Hepatitis C (Oct 2018)

Posted by Matt Breese on Oct 12, 2018

According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty

Trends That Matter for Specialty Drug Management

Posted by Matt Breese on Oct 11, 2018

Specialty drugs continue to be a concern for large employers, according to The Large Employers' 2019 Health Care Strategy and Plan Design Survey by the National Business Group on Health (NBGH), AIS Health reported.

NBGH surveyed its corporate members in May and June on what they are doing for 2019. When NBGH asked employers about specialty pharmacy benefit management techniques, respondents selected more aggressive utilization management protocols as the top strategy, with 64% citing this, followed by having employees get specialty drugs through a specialty pharmacy or the specialty department of the health plan or PBM, cited by 58%. At 44%, site-of-care management notched the third top technique.

Read More

Topics: Specialty, Industry Trends, Branding & Marketing, Data & Analytics

MMIT Reality Check on Hereditary Angioedema (Sep 2018)

Posted by Matt Breese on Oct 5, 2018

According to our recent payer coverage analysis for Hereditary Angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

MMIT Reality Check on HIV (Sep 2018)

Posted by Matt Breese on Sep 28, 2018

According to our recent payer coverage analysis for HIV treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

Radar On Market Access: Sensor-Equipped Pills Draw Plans’ Interest

Posted by Matt Breese on Sep 25, 2018

The In a move that one expert says Medicaid plans will be watching closely, Magellan Health and the drug manufacturer Otsuka America Pharmaceutical, Inc. said Aug. 30 that they will work together to allow "select regional provider networks" contracted through Magellan to opt into a program involving the Abilify MyCite system, AIS Health reported.
 
Abilify (aripiprazole) treats schizophrenia and other mental illnesses. The MyCite system comprises Abilify tablets embedded with sensors; patches that detect and record the date and time of the pill's ingestion as well as physiological data like activity level; an app that lets patients review their data and enter additional information; and a web-based dashboard that lets providers and caregivers display and track a patient's drug ingestion patterns over time.
 
Read More

Topics: Payer, Specialty, Market Access, Product Release

MMIT Reality Check on Rheumatoid Arthritis (Sep 2018)

Posted by Matt Breese on Sep 21, 2018

According to our recent payer coverage analysis for rheumatoid arthritis (RA) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Market Access, Branding & Marketing, Specialty, Payer

Perspectives on Step Therapy for Part B Drugs

Posted by Matt Breese on Sep 20, 2018

In a move that industry analysts see as a positive development for the managed care sector, CMS issued new guidance that will allow Medicare Advantage (MA) plans to use step therapy for Part B drugs starting in 2019, AIS Health reported.
 
CMS is giving MA plans that offer a Part D benefit the ability to "cross-manage" drugs across Part B and Part D. In other words, plans could require patients to try alternatives covered within Part D before moving on to relatively expensive physician-administered drugs in Part B, Credit Suisse analyst A.J. Rice explained in a research note.
 
Read More

Topics: Payer, Provider, Specialty

Radar On Market Access: NASHP Unveils PBM Model Act

Posted by Matt Breese on Sep 20, 2018

The National Academy for State Health Policy (NASHP) recently unveiled a model act aimed at helping states bring more transparency to PBMs, AIS Health reported.  
 
NASHP Executive Director Trish Riley says the academy's latest model legislation aimed at reining in prescription drug costs, which was developed in consultation with its pharmacy cost work group, is a compilation of states' recently enacted PBM laws. 
Read More

Topics: Industry Trends, Market Access, Specialty

Radar On Market Access: Indication-Based Formularies in Part D

Posted by Matt Breese on Sep 18, 2018

The Trump administration continues to take steps aimed at bringing down drug prices. In the latest move, CMS Administrator Seema Verma said in an Aug. 29 memo to Medicare Part D plan sponsors that they can begin using indication-based formularies in contract year 2020, AIS Health reported.
 
Starting in 2020, "Part D sponsors may utilize step therapy-like requirements within their [prior authorization] to promote cost-effective drug therapy by requiring the use of one formulary drug for a certain indication prior to authorizing coverage of a second drug for that indication," explains the memo.
Read More

Topics: Market Access, Specialty, Industry Trends